Rubinsztein DC - Search Results

1

α-Synuclein levels modulate Huntington's disease in mice.

Corrochano S, Renna M, Carter S, Chrobot N, Kent R, Stewart M, Cooper J, Brown SD, Rubinsztein DC, Acevedo-Arozena A. Corrochano S, et al. Among authors: rubinsztein dc. Hum Mol Genet. 2012 Feb 1;21(3):485-94. doi: 10.1093/hmg/ddr477. Epub 2011 Oct 18. Hum Mol Genet. 2012. PMID: 22010050 Free PMC article.

2

Haplotype analysis of the delta 2642 and (CAG)n polymorphisms in the Huntington's disease (HD) gene provides an explanation for an apparent 'founder' HD haplotype.

Rubinsztein DC, Leggo J, Goodburn S, Barton DE, Ferguson-Smith MA. Rubinsztein DC, et al. Hum Mol Genet. 1995 Feb;4(2):203-6. doi: 10.1093/hmg/4.2.203. Hum Mol Genet. 1995. PMID: 7757068

3

Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number.

Rubinsztein DC, Barton DE, Davison BC, Ferguson-Smith MA. Rubinsztein DC, et al. Hum Mol Genet. 1993 Oct;2(10):1713-5. doi: 10.1093/hmg/2.10.1713. Hum Mol Genet. 1993. PMID: 8268927 No abstract available.

4

Functional analysis of the Huntington's disease (HD) gene promoter.

Coles R, Caswell R, Rubinsztein DC. Coles R, et al. Among authors: rubinsztein dc. Hum Mol Genet. 1998 May;7(5):791-800. doi: 10.1093/hmg/7.5.791. Hum Mol Genet. 1998. PMID: 9536082

5

Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Rubinsztein DC, Wyttenbach A, Rankin J. Rubinsztein DC, et al. J Med Genet. 1999 Apr;36(4):265-70. J Med Genet. 1999. PMID: 10227391 Free PMC article. Review.

6

A molecular investigation of true dominance in Huntington's disease.

Narain Y, Wyttenbach A, Rankin J, Furlong RA, Rubinsztein DC. Narain Y, et al. Among authors: rubinsztein dc. J Med Genet. 1999 Oct;36(10):739-46. doi: 10.1136/jmg.36.10.739. J Med Genet. 1999. PMID: 10528852 Free PMC article.

7

Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.

Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC. Ho LW, et al. Among authors: rubinsztein dc. J Med Genet. 2001 Jul;38(7):450-2. doi: 10.1136/jmg.38.7.450. J Med Genet. 2001. PMID: 11432963 Free PMC article.

8

Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.

Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, Brown R, Maxwell M, Schapira A, Orntoft TF, Kato K, Rubinsztein DC. Wyttenbach A, et al. Among authors: rubinsztein dc. Hum Mol Genet. 2001 Aug 15;10(17):1829-45. doi: 10.1093/hmg/10.17.1829. Hum Mol Genet. 2001. PMID: 11532992

9

Lessons from animal models of Huntington's disease.

Rubinsztein DC. Rubinsztein DC. Trends Genet. 2002 Apr;18(4):202-9. doi: 10.1016/s0168-9525(01)02625-7. Trends Genet. 2002. PMID: 11932021 Review.

10

Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy.

Ravikumar B, Duden R, Rubinsztein DC. Ravikumar B, et al. Among authors: rubinsztein dc. Hum Mol Genet. 2002 May 1;11(9):1107-17. doi: 10.1093/hmg/11.9.1107. Hum Mol Genet. 2002. PMID: 11978769

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

450 results

Search Page

Filters